克唑替尼治疗洛拉替尼耐药伴MET扩增的EML4-ALK基因融合阳性晚期肺腺癌1例
Xinyi WANG, Ning MU, Mei LIU, Yue XU, Shengnan WU, Huan LV, Chunhua MA · 2024
Read 克唑替尼治疗洛拉替尼耐药伴MET扩增的EML4-ALK基因融合阳性晚期肺腺癌1例 by Xinyi WANG, Ning MU, Mei LIU, Yue XU, Shengnan WU, Huan LV, Chunhua MA (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11839500.txt.
Description
A patient whose lung cancer carried an ALK gene fusion did well on targeted drugs until the cancer outmaneuvered the strongest of them, lorlatinib. Xinyi Wang and co-authors report the case in detail. Testing the resistant tumor found a second alteration: amplification of the MET gene, a known escape route that reactivates growth signaling around the blocked target.
The team combined lorlatinib with crizotinib, an older drug that happens to block MET as well as ALK. The pairing brought the tumor back under control. The report, published in 2024, offers the combination as a practical reference for clinicians facing the same resistance pattern.
Catalog record
| CREATOR | Xinyi WANG, Ning MU, Mei LIU, Yue XU, Shengnan WU, Huan LV, Chunhua MA |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |